We share our knowledge
Key
publications
Long-term survival follow-up (4.6 years).
Shapira S, Vishnevsky G, Yaakobi H, et al. Reduced Mortality in COVID-19 Patients Treated With Inhaled Extracellular Vesicles Expressing CD24. Journal of Extracellular Vesicles. 2026;15:e70253. doi:10.1002/jev2.70253
No deaths among 35 EXO-CD24-treated patients versus 13.3% mortality in 105 matched controls over 4.6 years, with better long-term quality of life.
Randomized Phase IIb dose-finding study.
Grigoropoulos I, Tsioulos G, Kastrissianakis A, et al. The Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) in Mild-Moderate COVID-19 Related ARDS. Respiratory Research. 2024;25:151. doi:10.1186/s12931-024-02759-5
Randomized Phase IIb in 91 patients; no treatment-related adverse events.
Preclinical efficacy across respiratory diseases.
Shapira S, Schwartz R, Tsiodras S, et al. Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease. International Journal of Molecular Sciences. 2024;25(1):77. doi:10.3390/ijms25010077
Efficacy in models of sepsis, asthma, COPD and pulmonary fibrosis.
Compassionate use in severe ARDS.
Green O, Shenberg G, Baruch R, et al. Inhaled Exosomes Genetically Manipulated to Overexpress CD24 (EXO-CD24) as a Compassionate Use in Severe ARDS Patients. Biomedicines. 2023;11(9):2523. doi:10.3390/biomedicines11092523
11 critically ill, intubated ARDS patients; no recorded adverse events.
First-in-human study (Phase Ib/IIa).
Shapira S, Ben Shimon M, Hay-Levi M, et al. A Novel Platform for Attenuating Immune Hyperactivity Using EXO-CD24 in COVID-19 and Beyond. EMBO Molecular Medicine. 2022;14:e15997. doi:10.15252/emmm.202215997
35 hospitalized COVID-19 patients; safe and well tolerated, with rapid clinical improvement.
Reviews
Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. Life, 2022
The Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination. Vaccines, 2022
Media coverage
Conferences & Presentations
